Scientists develop effective intranasal mumps-based COVID-19 vaccine candidate

New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.

Study shows neutralizing antibodies to SARS-CoV-2 remain relatively high for up to 13 months following infection

  New York, NY – Researchers from the Icahn School of Medicine at Mount Sinai have found that most COVID-19 patients have persistent antibodies to the SARS-CoV-2 virus at levels that are correlated with neutralization of the virus more than…

Story Tips from Johns Hopkins Experts on COVID-19

Vaccines take time to work. After getting a COVID-19 vaccine, it takes a while for the immune system to fully respond and provide protection from the virus. For the Moderna and Pfizer COVID-19 vaccines, it takes up to two weeks after the second shot to become appropriately protected.

GenScript Granted Authorization for cPass™ SARS-CoV-2 Neutralization Antibody Detection Test in Brazil

GenScript USA Inc., the world’s leading research reagent provider, announced today that Brazil’s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.

Researchers develop new tools to rapidly test activity of anti-coronavirus antibodies

Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, described today in the Journal of Experimental Medicine (JEM), will help researchers understand whether patients are susceptible to reinfection by SARS-CoV-2 and assess the effectiveness of experimental vaccines, as well as develop antibody-based therapies against the disease.